Literature DB >> 7037150

Autologous bone marrow rescue in the treatment of advanced tumors of childhood.

H Ekert, W M Ellis, K D Waters, G P Tauro.   

Abstract

High-dose multiagent chemotherapy followed by autologous marrow rescue was used in the treatment of 13 patients with Stage III or IV childhood tumors. Encouraging results are being obtained in abdominal lymphoma (1/3 complete remissions (CR); rhabdomyosarcoma (2/4 CR); and retinoblastoma (1/2 CR). In neuroblastoma, the results are disappointing, with only one of four patients in CR; this patient developed a lymphoma associated with Epstein-Barr virus infection. Marrow reconstitution was obtained in 11 patients, with recovery of neutrophils to greater than 0.5 x 10(9)/liter between six and 30 days and platelet recovery to greater than 50 x 10(9)/liter between seven and 38 days. Investigations on the numbers of cells or committed granulocyte precursors ()CFU-c's) infused and parameters of hematologic recovery show poor correlation and suggest that a more accurate and reliable assay for the predictability of cryopreserved marrow to reconstitute marrow function within a reasonable time is necessary. Nonhematologic toxicities of high-dose multiagent chemotherapy are the principal dose-limiting factors.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7037150     DOI: 10.1002/1097-0142(19820201)49:3<603::aid-cncr2820490334>3.0.co;2-h

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

Review 1.  Chemotherapy for retinoblastoma: a current topic.

Authors:  P T Finger; G Czechonska; H Demirci; A Rausen
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Investigations of the simian ontogenic switch from fetal to adult hemoglobin at the progenitor cell level.

Authors:  B P Alter; R S Weinberg; D C Linch; J M Schofield; B T Jackson; G J Piasecki; J C Thornton; D G Nathan
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

3.  High dose melphalan in children with advanced malignant disease. A pharmacokinetic study.

Authors:  J Ninane; R Baurain; A de Selys; A Trouet; G Cornu
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 4.  Intensive chemotherapy for solid tumours--current clinical applications.

Authors:  S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

5.  Granulocyte-macrophage colony stimulating factor (GM-CSF) after high-dose melphalan in patients with advanced colon cancer.

Authors:  W P Steward; J H Scarffe; L Y Dirix; J Chang; J A Radford; E Bonnem; D Crowther
Journal:  Br J Cancer       Date:  1990-05       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.